Arrowhead Pharmaceuticals Q2 2020 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported a revenue of $23,528,853 and a net loss of $19,835,570 for the fiscal second quarter ended March 31, 2020.
Dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD.
Completed enrollment of the first sequential cohort in the AROAAT2002 study, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease.
Completed planned enrollment in AROANG1001, a Phase 1 clinical study of ARO-ANG3.
Completed discovery and optimization work and advanced ARO-Lung2 into IND-enabling studies with a planned CTA filing in in the first half of 2021.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
No forward guidance was provided in the press release.